Expansion of Orders for the Metabolome Analysis Business
First written in FY2016-Q4. 19 of 36 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Strong performance in new services alongside declining revenue from existing servicesAnnual report
「By service, orders for biomanufacturing support services remained strong after their launch in July, generating revenue of ¥127.226 million, exceeding the annual revenue target. Functional materials development support services also increased revenue to ¥363.885 million, up 16.6% from the previous consolidated fiscal year, as orders for services including health-claim measurement packages remained strong. Meanwhile, life sciences research support services declined to ¥930.832 million, down 18.6%, because large projects in the domestic academic sector decreased and overseas sales also fell substantially amid lower demand across the market.」
Biomanufacturing support services exceeded the annual revenue target, and functional materials development support services also reported higher revenue. Life sciences research support services, however, reported lower revenue because of fewer large domestic projects and weaker overseas demand. - 2026-08-07OtherEarnings
「In addition to the life science research support service and the functional materials development support service, our group began providing a bio-manufacturing support service and conducted activities aimed at expanding orders.」
The company continued activities to expand orders and newly included the launch of the bio-manufacturing support service, while revenue declined 2.3% from the previous consolidated fiscal year. - FY2026-H1Launch of new services alongside declining revenue from existing servicesAnnual report
「Against this backdrop, the Group began providing biomanufacturing support services in addition to life sciences research support services and functional materials development support services, and worked to expand orders.」
While the Group launched biomanufacturing support services and worked to expand orders, overall revenue declined 3.7% year on year because of lower U.S. sales in the life sciences research support services, fewer projects for pharmaceutical companies, and fewer large projects for food companies. - FY2025-H1Higher revenue from large domestic projects alongside lower revenue in Europe and the United StatesAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business and the Healthcare Solutions Business, centered on comprehensive support services for functional materials development, through vigorous sales activities for high-sensitivity comprehensive analysis services.」
While continuing efforts to expand orders, the Advanced Research and Development Support Business reported higher revenue due to orders brought forward in Japan and large projects in the food and pharmaceutical sectors. In Europe and the United States, however, revenue declined because orders were difficult to secure and revenue recognition was delayed. - FY2024Higher order backlog alongside lower revenueAnnual report
「The Group sought to expand orders in the Advanced Research and Development Support Business, centered on high-sensitivity comprehensive analysis services, and the Healthcare Solutions Business, centered on comprehensive support services for functional materials development. In the Advanced Research and Development Support Business, overseas pharmaceutical sales increased, but sales declined mainly in domestic academia and pharmaceuticals, resulting in lower revenue year on year.」
The Group continued measures to expand orders, but the Advanced Research and Development Support Business reported lower revenue and profit, with revenue of ¥1,186.852 million and segment profit of ¥310.700 million. Meanwhile, the order backlog increased from ¥427.910 million to ¥527.684 million, indicating progress in orders. - FY2024-Q3WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the Healthcare Solutions Business, centered on the Advanced Research and Development Support Business and comprehensive support services for functional materials development, through vigorous sales activities for high-sensitivity comprehensive analysis services. In the Advanced Research and Development Support Business, sales in food and chemicals increased, but sales in academia and pharmaceuticals declined, resulting in lower revenue year on year.」
The Group continued sales activities for high-sensitivity comprehensive analysis services, but revenue in the Advanced Research and Development Support Business declined because of lower sales in academia and pharmaceuticals. - FY2024-Q2WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the Healthcare Solutions Business, centered on the Advanced Research and Development Support Business and comprehensive support services for functional materials development, through vigorous sales activities for high-sensitivity comprehensive analysis services. In the Advanced Research and Development Support Business, sales in pharmaceuticals increased, but sales in academia declined by more, resulting in lower revenue year on year.」
The Group continued expanding orders through sales activities for high-sensitivity comprehensive analysis services, but the decline in academic sales in the Advanced Research and Development Support Business exceeded the increase in pharmaceutical sales, resulting in lower revenue. - FY2024-Q1WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the Healthcare Solutions Business, centered on the Advanced Research and Development Support Business and comprehensive support services for functional materials development, through vigorous sales activities for high-sensitivity comprehensive analysis services. However, revenue declined year on year because of the timing of revenue recognition for large projects.」
The Group continued sales activities to expand orders, but consolidated revenue declined 10.4% year on year because of the impact of the timing of revenue recognition for large projects. - FY2023AdvancedAnnual report
「In this business segment, sales of high-sensitivity comprehensive analysis services for metabolites and other omics contract services introduced from partner companies remained steady both in Japan and overseas. Sales increased mainly in pharmaceuticals, and efforts to reduce general and administrative expenses also contributed to higher revenue and profit.」
In the Advanced Research and Development Support Business, revenue was ¥1,251.738 million, up 2.6% year on year, and the order backlog was ¥427.910 million, compared with ¥398.361 million at the end of the previous fiscal year, indicating progress in expanding orders and sales. - FY2023-Q3AdvancedAnnual report
「In this business segment, sales of high-sensitivity comprehensive analysis services for metabolites and other omics contract services introduced from partner companies to expand the service offering remained steady both in Japan and overseas, driving higher sales mainly in academia and pharmaceuticals. Sales of contract metabolite analysis services in Europe and the United States also increased substantially. As a result, revenue was ¥1,045.761 million, up 3.8% year on year, and segment profit after allocation of company-wide expenses was ¥373.253 million, up 4.1%.」
Sales of high-sensitivity comprehensive analysis services and other omics contract services introduced from partner companies remained steady in Japan and overseas, while sales in Europe and the United States also increased substantially. The Advanced Research and Development Support Business reported higher revenue and profit. - FY2023-Q2AdvancedAnnual report
「Against this backdrop, the Group worked vigorously to sell high-sensitivity comprehensive analysis services for metabolites, thereby seeking to expand orders in the Advanced Research and Development Support Business, while continuing to reduce general and administrative expenses excluding research and development expenses.」
The Group continued sales activities for high-sensitivity comprehensive analysis services, and revenue in the Advanced Research and Development Support Business was ¥587.789 million, up 10.6% year on year. - FY2023-Q1AdvancedAnnual report
「Against this backdrop, the Group worked vigorously to sell high-sensitivity comprehensive analysis services, thereby seeking to expand orders in the Advanced Research and Development Support Business, while continuing to reduce general and administrative expenses excluding research and development expenses. As a result, revenue for the first quarter cumulative consolidated period increased substantially to ¥262.484 million, up 51.3% year on year.」
The Group advanced sales activities for high-sensitivity comprehensive analysis services, resulting in a 51.3% year-on-year increase in consolidated revenue. - FY2022AdvancedAnnual report
「The Group significantly increased orders and, consequently, sales by expanding sales of its high-sensitivity comprehensive analysis services, which provide high added value. As a result, the order backlog in the Advanced Research and Development Support Business at the end of the consolidated fiscal year was ¥398.361 million, compared with ¥199.325 million at the end of the previous consolidated fiscal year.」
Driven by expanded sales of high-sensitivity comprehensive analysis services, orders in the Advanced Research and Development Support Business were ¥1,400.598 million and the order backlog was ¥398.361 million, up from ¥199.325 million at the end of the previous fiscal year. - FY2022-Q3AdvancedAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business, formerly the metabolomics business, through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. These activities led to a substantial increase in orders from October of the previous year, and the Group achieved its highest-ever revenue for a third quarter cumulative consolidated period.」
While continuing web-based sales and other activities, the Group saw a substantial increase in orders from October of the previous year and achieved its highest-ever revenue for a third quarter cumulative consolidated period. - FY2022-Q2AdvancedAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business, formerly the metabolomics business, through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. These activities led to a substantial increase in orders from October, after the fourth state of emergency was lifted, and the Group achieved its highest-ever revenue for a second quarter consolidated accounting period, covering October to December.」
While continuing web-based sales activities, the Group saw a substantial increase in orders from October and achieved its highest-ever revenue for a second quarter consolidated accounting period. - FY2022-Q1WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business, formerly the metabolomics business, through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. Although most of the first quarter was under a state of emergency, orders remained steady. However, revenue for the first quarter cumulative consolidated period declined substantially year on year because measurement samples were delayed under the state of emergency and for other reasons.」
The Group continued web-based sales activities and efforts to expand orders. Orders remained steady, but revenue declined substantially year on year because measurement samples were delayed and for other reasons. - FY2021WorsenedAnnual report
「During the consolidated fiscal year, delays in research plans, including large-scale human studies, resulted in scheduled orders being postponed, and orders declined from the previous consolidated fiscal year.」
The Group worked on web-based sales and recognizing revenue from the previous fiscal year's order backlog, but orders declined because research plans were delayed and scheduled orders were postponed. The order backlog in the metabolomics business also decreased from ¥321.950 million to ¥199.325 million. - FY2021-Q3WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the metabolomics business through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. However, during the third quarter consolidated accounting period, both orders and sales declined because scheduled orders were postponed and measurement samples were delayed, resulting in lower revenue for the third quarter cumulative consolidated period as well.」
The Group continued measures to expand orders through web-based sales and other activities, but orders and sales declined because scheduled orders were postponed and measurement samples were delayed. - FY2021-Q2AdvancedAnnual report
「Against this backdrop, the Group sought to expand orders in the metabolomics business through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. It also achieved higher revenue for the second quarter cumulative consolidated period by reliably delivering services for projects already ordered.」
The Group advanced web-based sales activities and reliable delivery of services for projects already ordered, bringing consolidated revenue to ¥537.439 million, up 18.2% year on year. - FY2021-Q1AdvancedAnnual report
「The Group sought to expand orders in the metabolomics business through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. Revenue for the first quarter cumulative consolidated period increased as the Group reliably delivered services for projects already ordered. As a result, revenue for the first quarter cumulative consolidated period was ¥245.718 million, up 23.9% year on year, due to the expansion of the metabolomics business.」
The Group advanced web-based sales activities and reliable delivery of services for projects already ordered, resulting in a 23.9% year-on-year increase in consolidated revenue. - FY2020AdvancedAnnual report
「As sales remained strong across all fields, particularly chemicals and food, revenue for the consolidated fiscal year reached ¥1,118.495 million, the highest level since the company's founding.」
The Group advanced promotional activities, strengthened its sales structure and expanded orders for large projects, bringing revenue to its highest level since the company's founding. The order backlog also increased to ¥324.950 million from ¥266.674 million at the end of the previous fiscal year. - FY2020-Q3AdvancedAnnual report
「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to expand orders for large projects. As a result, sales increased across all fields compared with the corresponding period of the previous year, 1 July 2018 to 31 March 2019. The Group also reviewed its sales strategy and worked to strengthen its sales structure.」
The company stated that sales increased across all fields while it worked to expand orders for large projects, demonstrating concrete progress in order expansion. - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group continued efforts to expand orders in the metabolomics business, focusing on promotional activities such as exhibiting at academic conferences in Japan and overseas and running campaigns, while also focusing on organizational strengthening to improve sales and production efficiency.」
The Group continued expanding orders through exhibitions at academic conferences in Japan and overseas and campaigns, as well as strengthening its organization. Sales to the chemicals and food sectors were strong, and revenue from the metabolomics business was ¥453.226 million, although no year-on-year comparison was made because the fiscal year-end was changed. - FY2020-Q1RestatedAnnual report
「Against this backdrop, the Group continued efforts to expand orders in the metabolomics business, focusing on promotional activities such as exhibiting at academic conferences in Japan and overseas and running campaigns, while also focusing on organizational strengthening to improve sales and production efficiency.」
The Group continued expanding orders through exhibitions at academic conferences in Japan and overseas and campaigns, while also strengthening its organization to improve sales and production efficiency. - FY2019AdvancedAnnual report
「The order backlog at the end of the consolidated fiscal year was ¥266.674 million, up substantially from ¥177.217 million at the end of the previous consolidated fiscal year.」
Orders of ¥1,076.581 million and an order backlog of ¥266.674 million were recorded, demonstrating full-year progress in expanding orders. - FY2019-Q3RestatedAnnual report
「Against this backdrop, the Group continued efforts to expand orders in the metabolomics business, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on expanding overseas markets and launching new services. As a result, revenue for the fourth quarter cumulative consolidated period was ¥834.125 million, although orders in the metabolomics business were trending toward recovery, mainly because customers' budget execution was sluggish in the first half.」
The Group continued promotional activities, overseas market expansion and new service launches. Orders were described as trending toward recovery, but revenue was ¥834.125 million because customers' budget execution was sluggish in the first half. - FY2019-Q2WorsenedAnnual report
「Against this backdrop, the Group continued efforts to expand orders in the metabolomics business, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on expanding overseas markets and launching new services. As a result, revenue for the third quarter cumulative consolidated period was ¥438.666 million, down 15.6% year on year, although orders in the metabolomics business were trending toward recovery, mainly because customers' budget execution was sluggish in the first half.」
Orders were described as trending toward recovery, but cumulative revenue fell 15.6% year on year because customers' budget execution was sluggish in the first half. - FY2019-Q1WorsenedAnnual report
「Against this backdrop, the Group continued efforts to expand orders in the metabolomics analysis business, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on expanding overseas markets and launching new services. As a result, revenue for the second quarter cumulative consolidated period was ¥276.434 million, down 10.1% year on year, mainly because orders for large projects were pushed back to the second half or later.」
The Group continued promotional activities, overseas market expansion and new service launches, but orders for large projects were pushed back to the second half or later, resulting in a 10.1% year-on-year decline in cumulative revenue. - FY2018-Q4AdvancedAnnual report
「The Group continued efforts to expand orders in the metabolomics analysis business, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on expanding overseas markets and launching new services. As a result, revenue for the first quarter cumulative consolidated period was ¥150.868 million, up 28.3% year on year, supported by progress in receiving samples for projects won in the previous fiscal year and other factors.」
The Group continued promotional activities and other efforts to expand orders, while consolidated revenue increased 28.3% year on year, supported by progress in receiving samples for projects won in the previous fiscal year. - FY2018-Q2AdvancedAnnual report
「The order backlog reached ¥346.025 million, an increase of ¥237.009 million, or 217.4%, from the end of the previous consolidated fiscal year. This was because, given the characteristics of the business, revenue recognition increases toward the fourth quarter consolidated accounting period, resulting in a higher order backlog at the end of the third quarter consolidated accounting period.」
The order backlog in the metabolomics analysis business reached ¥346.025 million, up 217.4% from the end of the previous consolidated fiscal year, demonstrating concrete progress in expanding orders. - FY2018-Q1AdvancedAnnual report
「The order backlog reached ¥313.191 million, an increase of ¥204.174 million, or 187.3%, from the end of the previous consolidated fiscal year.」
The order backlog in the metabolomics analysis business reached ¥313.191 million, up 187.3% from the end of the previous consolidated fiscal year, demonstrating concrete progress in expanding orders. - FY2017-Q4AdvancedAnnual report
「Against this backdrop, the Group worked to expand orders in the metabolomics analysis business, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on expanding overseas markets and developing new services. As a result, revenue for the first quarter cumulative consolidated period was ¥117.547 million, up 25.9% year on year, supported by steady orders and sales in the metabolomics analysis business.」
The Group continued efforts to expand orders through promotional activities and other measures, and consolidated revenue increased 25.9% year on year as orders and sales in the metabolomics analysis business remained steady. - FY2017AdvancedAnnual report
「As orders for the metabolomics analysis business remained strong, annual revenue increased significantly to ¥914.180 million, up 17.1% year on year.」
Revenue from the metabolomics analysis business was ¥913.458 million, up 29.8% year on year, while orders were ¥922.156 million, up 130.9%, demonstrating full-year progress in expanding orders. - FY2017-Q2AdvancedAnnual report
「The order backlog reached ¥301.472 million, an increase of ¥201.249 million, or 200.8%, from the end of the previous consolidated fiscal year. This was because, given the characteristics of the business, revenue recognition increases toward the fourth quarter consolidated accounting period, resulting in a higher order backlog at the end of the third quarter consolidated accounting period.」
The order backlog in the metabolomics analysis business reached ¥301.472 million, up 200.8% from the end of the previous consolidated fiscal year, demonstrating concrete progress in expanding orders. - FY2017-Q1AdvancedAnnual report
「As a result, revenue was ¥273.190 million, up 11.4% year on year, and segment profit was ¥83.293 million, up 95.3%.」
Orders remained strong, driving year-on-year increases in revenue and segment profit. The order backlog also reached ¥250.520 million, an increase of 150.0% from the end of the previous consolidated fiscal year, demonstrating concrete progress. - FY2016-Q4First statedAnnual report
「In the metabolomics analysis business, we worked to expand orders, focusing on promotional activities such as exhibiting at academic conferences and running campaigns, while also focusing on developing overseas markets and cultivating new markets.」
The company identified expanding orders through promotional activities as a key initiative.